Block & Leviton LLP is investigating Replimune Group following the company's announcement that it had received a Complete Response Letter from the U.S. Food and Drug Administration, rejecting the company’s application for its advanced melanoma therapy due to insufficient clinical evidence from Replimune's Phase 2 study. The company's stock has fallen over 70% following the announcement.
Contact our attorneys for a no-cost case evaluation.